This medispa's peptide therapy claims, fact-checked

What did @totality_medispa actually say?

The video's caption does most of the heavy lifting here. Jen, the featured client, says she loves the way she looks and credits Totality with boosting her confidence after three years. That's a testimonial, not a medical claim. But the caption frames NAD+ as supporting "cellular longevity and repair," GLP-1 as delivering "metabolic weight management," and Melanotan as producing "a sun-kissed glow from within." Those are the actual claims being made, and they deserve scrutiny.

Jen's words are warm but vague. She doesn't describe a protocol, a dose, or a specific result beyond liking her reflection. The caption is doing the selling. When a med spa pairs a glowing testimonial with a peptide menu that includes a drug flagged by multiple national regulators, viewers deserve to know what they're actually looking at.

Does the science back this up?

It depends entirely on which compound you're asking about. NAD+ precursor research is real and active. GLP-1 receptor agonists have a robust clinical evidence base. Melanotan is a different story entirely, and bundling it with the other two in a wellness aesthetic package glosses over a significant safety and regulatory gap.

NAD+ boosting via precursors like NMN or NR has shown promise in early human trials. Yoshino et al. (2021, Science) found NMN improved muscle insulin sensitivity in postmenopausal women. That's interesting but preliminary. The leap from that to "cellular longevity" is marketing language, not a clinical conclusion.

GLP-1 receptor agonists (semaglutide, tirzepatide) have genuine phase 3 trial data behind them. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide producing up to 22.5% body weight reduction. The metabolic weight management claim is the most defensible one in this video.

Melanotan II is a synthetic analog of alpha-MSH that stimulates melanocortin receptors. The FDA has never approved it. It has been linked to nausea, spontaneous erections, changes in existing moles, and at least one case report of melanoma (Evans-Brown et al., 2009, BMJ). Calling it a route to a "sun-kissed glow" omits that context entirely.

What did they get wrong (or right)?

They got GLP-1 basically right. Framing semaglutide-class drugs as "metabolic weight management" is accurate and consistent with how prescribers discuss them. Credit where it's due.

The NAD+ claim is overstated but not fabricated. "Cellular longevity and repair" is ahead of the current evidence in humans, but the underlying biology isn't invented. The problem is presenting a hypothesis as a settled outcome.

The Melanotan claim is where this video crosses a line. Describing an unapproved, unscheduled peptide analog with a documented adverse event profile as a cosmetic wellness tool, in a caption next to a glowing client testimonial, is misleading. The FDA issued import alerts on Melanotan II. The World Anti-Doping Agency bans it. Several European countries have explicitly prohibited its sale. None of that context appears here.

Bundling Melanotan with GLP-1 and NAD+ also creates a halo effect. Viewers who recognize GLP-1 as legitimate may assume the whole stack carries similar regulatory standing. It does not.

What should you actually know?

If you're considering any of these compounds, the regulatory status matters as much as the science. GLP-1 receptor agonists are FDA-approved drugs with prescribing guidelines, contraindications, and monitoring requirements. They belong in a clinical conversation with a licensed provider, not just a caption.

NAD+ precursors are sold as supplements in the U.S. and are not FDA-approved as drugs. The research is early-stage. You are not guaranteed the results suggested by "longevity and repair" language.

Melanotan II is not approved by the FDA, the EMA, or most comparable regulatory bodies. It is not a licensed aesthetic treatment. Purchasing it typically means obtaining it from unregulated sources, which introduces contamination and dosing risks that have no clinical oversight. A med spa offering it as part of a cosmetic package is operating outside sanctioned medical practice in most jurisdictions.

The aesthetic procedures listed (filler, neuromodulator, microneedling) are in a separate regulatory category and are not the focus of this fact-check. The peptide stack is.

• Ask any prescriber offering Melanotan II which regulatory body has approved it, and for what indication.
• Request peer-reviewed evidence, not testimonials, before starting any peptide protocol.
• GLP-1 therapy has real risks including pancreatitis and thyroid concerns. That belongs in an informed consent conversation.